Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173821
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | López Muñoz, Gerardo A. | - |
dc.contributor.author | Ortega, María Alejandra | - |
dc.contributor.author | Ferret-Miñana, Ainhoa | - |
dc.contributor.author | De Chiara, Francesco | - |
dc.contributor.author | Azcón, Javier Ramón | - |
dc.date.accessioned | 2021-02-10T15:28:25Z | - |
dc.date.available | 2021-02-10T15:28:25Z | - |
dc.date.issued | 2020-12-15 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173821 | - |
dc.description | Reproducció del document publicat a: https://doi.org/10.3390/nano10122520 | ca |
dc.description.abstract | Non-alcoholic fatty liver (NAFLD) is a metabolic disorder related to a chronic lipid accumulation within the hepatocytes. This disease is the most common liver disorder worldwide, and it is estimated that it is present in up to 25% of the world’s population. However, the real prevalence of this disease and the associated disorders is unknown mainly because reliable and applicable diagnostic tools are lacking. It is known that the level of albumin, a pleiotropic protein synthesized by hepatocytes, is correlated with the correct function of the liver. The development of a complementary tool that allows direct, sensitive, and label-free monitoring of albumin secretion in hepatocyte cell culture can provide insight into NAFLD’s mechanism and drug action. With this aim, we have developed a simple integrated plasmonic biosensor based on gold nanogratings from periodic nanostructures present in commercial Blu-ray optical discs. This sensor allows the direct and label-free monitoring of albumin in a 2D fatty liver disease model under flow conditions using a highly-specific polyclonal antibody. This technology avoids both the amplification and blocking steps showing a limit of detection within pM range (≈0.26 ng/mL). Thanks to this technology, we identified the optimal fetal bovine serum (FBS) concentration to maximize the cells’ lipid accumulation. Moreover, we discovered that the hepatocytes increased the amount of albumin secreted on the third day from the lipids challenge. These data demonstrate the ability of hepatocytes to respond to the lipid stimulation releasing more albumin. Further investigation is needed to unveil the biological significance of that cell behavior. | ca |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.relation.ispartof | Nanomaterials, 2020, vol. 10, num. 12 | - |
dc.relation.uri | https://doi.org/10.3390/nano10122520 | - |
dc.rights | cc by (c) López Muñoz et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Malalties del fetge | - |
dc.subject.classification | Cèl·lules hepàtiques | - |
dc.subject.classification | Materials nanoestructurats | - |
dc.subject.other | Liver diseases | - |
dc.subject.other | Liver cells | - |
dc.subject.other | Nanostructured materials | - |
dc.title | Direct and label-free monitoring of albumin in 2D fatty liver disease model using plasmonic nanogratings | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/714317/EU//DAMOC | ca |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/863037/EU//BLOC | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
dc.identifier.pmid | 33334062 | - |
Appears in Collections: | Publicacions de projectes de recerca finançats per la UE Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
L25_2020_Nanomaterials_10_2520_OA.pdfv3.pdf | 25.47 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License